Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury

Free Radical Biology and Medicine

Volumn 42, Issue 12, 2007, Pages 1818-1825

  Daosukho, Chotiros ^a,b   Chen, Yumin ^a   Noel, Teresa ^a   Sompol, Pradoldej ^a   Nithipongvanitch, Ramaneeya ^c   Velez, Joyce M ^a   Oberley, Terry D ^c   St Clair, Daret K ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Adriamycin; Antioxidant; Heart; Histone deacetylase inhibitor; Mitochondria; Oxidative stress; Sodium phenylbutyrate

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CREATINE KINASE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; LACTATE DEHYDROGENASE; MANGANESE SUPEROXIDE DISMUTASE; SODIUM CHLORIDE; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME LOCALIZATION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INJURY; HEART PROTECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE STRUCTURE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CREATINE KINASE; DOXORUBICIN; ECHOCARDIOGRAPHY; HEART; HISTONE DEACETYLASES; L-LACTATE DEHYDROGENASE; MALE; MICE; MICE, INBRED C57BL; MYOCYTES, CARDIAC; PHENYLBUTYRATES; SUPEROXIDE DISMUTASE;

MUS;

EID: 34248591511     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.03.007     Document Type: Article

References (52)

1. Horan P.G., McMullin M.F., and McKeown P.P. Anthracycline cardiotoxicity. Eur. Heart J. 27 (2006) 1137-1138
2. Singal P.K., and Iliskovic N. Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339 (1998) 900-905
3. 2- and p53-dependent pathways. J. Biol. Chem. 279 (2004) 25535-25543
4. Darpa P., and Liu L.F. Topoisomerase-targeting antitumor drugs. Biochim. Biophys. Acta 989 (1989) 163-177
5. Doroshow J.H. Effect of anthracycline antibiotics on oxygen radical formation in rat-heart. Cancer Res. 43 (1983) 460-472
6. Vasquezvivar J., Martasek P., Hogg N., Masters B.S.S., Pritchard K.A., and Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry 36 (1997) 11293-11297
7. Lebrecht D., Kokkori A., Ketelsen U.P., Setzer B., and Walker U.A. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J. Pathol. 207 (2005) 436-444
8. Kusuoka H., Futaki S., Koretsune Y., Kitabatake A., Suga H., Kamada T., et al. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart-failure. J. Cardiovasc. Pharmacol. 18 (1991) 437-444
9. Solem L.E., Henry T.R., and Wallace K.B. Disruption of mitochondrial calcium homeostasis following chronic doxorubicin administration. Toxicol. Appl. Pharmacol. 129 (1994) 214-222
10. Minotti G., Cairo G., and Monti E. Role of iron in anthracycline cardiotoxicity: New tunes for an old song?. FASEB J. 13 (1999) 594
11. Kotamraju S., Chitambar C.R., Kalivendi S.V., Joseph J., and Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - role of oxidant-induced iron signaling in apoptosis. J. Biol. Chem. 277 (2002) 17179-17187
12. Chen Y., Daosukho C., Opii W.O., Turner D.M., Pierce W.M., Klein J.B., et al. Redox proteomic identification of oxidized cardiac proteins in adriamycin-treated mice. Free Rad. Biol. Med. 41 (2006) 1470-1477
13. Singal P.K., Siveskiiliskovic N., Hill M., Thomas T.P., and Li T.M. Combination therapy with probucol prevents adriamycin-induced cardiomyopathy. J. Mol. Cell. Cardiol. 27 (1995) 1055-1063
14. Seifert C.F., Nesser M.E., and Thompson D.F. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann. Pharmacotherapy 28 (1994) 1063-1072
15. Chua C.C., Liu X., Gao J., Hamdy R.C., and Chua B.H.L. Multiple actions of pifithrin-α on doxorubicin-induced apoptosis in rat myoblastic H9C2 cells. Am. J. Physiol. Heart. Circ. Physiol. 290 (2006) H2606-H2613
16. Li K., Sung R.Y.T., Huang W.Z., Yang M., Pong N.H., Lee S.M., et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 113 (2006) 2211-2220
17. Daosukho C., Ittarat W., Lin S.M., Sawyer D.B., Kiningham K., Lien Y.C., et al. Induction of manganese superoxide dismutase (MnSOD) mediates cardioprotective effect of tamoxifen (TAM). J. Mol. Cell. Cardiol. 39 (2005) 792-803
18. Lund A.H., and van Lohuizen M. Epigenetics and cancer. Genes Dev. 18 (2004) 2315-2335
19. Baylin S.B., and Ohm J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat. Rev. Cancer 6 (2006) 107
20. McKinsey T.A., and Olson E.N. Toward transcriptional therapies for the failing heart: Chemical screens to modulate genes. J. Clin. Invest. 115 (2005) 538-546
21. Barnes P.J., Adcock I.M., and Ito K. Histone acetylation and deacetylation: Importance in inflammatory lung diseases. Eur. Respirat. J. 25 (2005) 552-563
22. Saha R.N., and Pahan K. Hats and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis. Cell Death Differentiation 13 (2006) 539-550
23. Bolden J.E., Peart M.J., and Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5 (2006) 769-784
24. Maehara K., Uekawa N., and Isobe K.I. Effects of histone acetylation on transcriptional regulation of manganese superoxide dismutase gene. Biochem. Biophys. Res. Commun. 295 (2002) 187-192
25. Liu T., Kuljaca S., Tee A., and Marshall G.M. Histone deacetylase inhibitors: Multifunctional anticancer agents. Cancer Treat. Rev. 32 (2006) 157-165
26. Carducci M.A., Gilbert J., Bowling M.K., Noe D., Eisenberger M.A., Sinibaldi V., et al. A phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7 (2001) 3047-3055
27. Qi X., Hosoi T., Okuma Y., Kaneko M., and Nomura Y. Sodium 4-phenylbutyrate protects against cerebral ischemic injury. Mol. Pharmacol. 66 (2004) 899-908
28. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 93 (2005) 1087-1098
29. Ozcan U., Yilmaz E., Ozcan L., Furuhashi M., Vaillancourt E., Smith R.O., et al. Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313 (2006) 1137-1140
30. Liu X.L., Done S.C., Yan K., Kilpelainen P., Pikkarainen T., and Tryggvason K. Defective trafficking of nephrin missense mutants rescued by a chemical chaperone. J. Am. Soc. Nephrol. 15 (2004) 1731-1738
31. Scaglia F., Carter S., O'Brien W.E., and Lee B. Effect of alternative pathway therapy on branched chain amino acid metabolism in urea cycle disorder patients. Mol. Genet. Metabol. 81 (2004) S79-S85
32. Maestri N.E., Brusilow S.W., Clissold D.B., and Bassett S.S. Long-term treatment of girls with ornithine, transcarbamylase deficiency. N. Engl. J. Med. 335 (1996) 855-859
33. Yen H.C., Oberley T.D., Vichitbandha S., Ho Y.S., and Stclair D.K. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98 (1996) 1253-1260
34. Chaiswing L., Cole M., St. Clair D., Ittarat W., Szweda L., and Oberley T. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury. Toxicol. Pathol. 32 (2004) 536-547
35. Spitz D.R., and Oberley L.W. An assay for superoxide dismutase activity in mammalian tissue homogenates. Anal. Biochem. 179 (1989) 8-18
36. Yen H.C., Oberley T.D., Gairola C.G., Szweda L.I., and St Clair D.K. Manganese superoxide dismutase protects mitochondrial complex I against adriamycin-induced cardiomyopathy in transgenic mice. Arch. Biochem. Biophys. 362 (1999) 59-66
37. Goffart S., von Kleist-Retzow J.C., and Wiesner R.J. Regulation of mitochondrial proliferation in the heart: Power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc. Res. 64 (2004) 198-207
38. Kubota K., Niinuma Y., Kaneko M., Okuma Y., Sugai M., Omura T., et al. Suppressive effects of 4-phenylbutyrate on the aggregation of Pael receptors and endoplasmic reticulum stress. J. Neurochem. 97 (2006) 1259-1268
39. Vilatoba M., Eckstein C., Bilbao G., Smyth C.A., Jenkins S., Thompson J.A., et al. Sodium 4-phenylbutyrate protects against liver ischemia reperfusion injury by inhibition of endoplasmic reticulum-stress mediated apoptosis. Surgery 138 (2005) 342-351
40. Kim S.J., Park K.M., Kim N., and Yeom Y.I. Doxorubicin prevents endoplasmic reticulum stress-induced apoptosis. Biochem. Biophys. Res. Commun. 339 (2006) 463-468
41. Brown H.R., Ni H., Benavides G., Yoon L., Hyder K., Giridhar J., et al. Correlation of simultaneous differential gene expression in the blood and heart with known mechanisms of adriamycin-induced cardiomyopathy in the rat. Toxicol. Pathol. 30 (2002) 452-469
42. Lien Y.C., Noel T., Liu H., Stromberg A.J., Chen K.C., and St. Clair D.K. Phospholipase C-delta 1 is a critical target for tumor necrosis factor receptor-mediated protection against adriamycin-induced cardiac injury. Cancer Res. 66 (2006) 4329-4338
43. Rahman I., Marwick J., and Kirkham P. Redox modulation of chromatin remodeling: Impact on histone acetylation and deacetylation, NF-kappa B and pro-inflammatory gene expression. Biochem. Pharmacol. 68 (2004) 1255-1267
44. Adcock I.M., Cosio B., Tsaprouni L., Barnes P.J., and Ito K. Redox regulation of histone deacetylases and glucocorticoid-mediated inhibition of the inflammatory response. Antioxidants Redox Signal. 7 (2005) 144-152
45. Poizat C., Sartorelli V., Chung G., Kloner R.A., and Kedes L. Proteasome-mediated degradation of the coactivator p300 impairs cardiac transcription. Mol. Cell. Biol. 20 (2000) 8643-8654
46. Poizat C., Puri P.L., Bai Y., and Kedes L. Phosphorylation-dependent degradation of p300 by doxorubicin-activated p38 mitogen-activated protein kinase in cardiac cells. Mol. Cell. Biol. 25 (2005) 2673-2687
47. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J. Clin. Oncol. 23 (2005) 3971-3993
48. Rosenoff S.H., Olson H.M., Young D.M., Bostick F., and Young R.C. Adriamycin-induced cardiac damage in mouse - small-animal model of cardiotoxicity. J. Nat. Cancer Ins. 55 (1975) 191-194
49. Lien Y.C., Lin S.M., Nithipongvanitch R., Oberley T.D., Noel T., Zhao Q., et al. Tumor necrosis factor receptor deficiency exacerbated adriamycin-induced cardiomyocytes apoptosis: An insight into the Fas connection. Mol. Cancer Therapeutics 5 (2006) 261-269
50. Yi X.M., Bekeredjian R., Defilippis N.J., Siddiquee Z., Fernandez E., and Shohet R.V. Transcriptional analysis of doxorubicin-induced cardiotoxicity. Am. J. Physiol. Heart Circul. Physiol. 290 (2006) H1098-H1102
51. Lebrecht D., Setzer B., Ketelsen U.P., Haberstroh J., and Walker U.A. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation 108 (2003) 2423-2429
52. Piscitelli S.C., Rodvold K.A., Rushing D.A., and Tewksbury D.A. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small-cell lung-cancer. Clin. Pharmacol. Therapeutics 53 (1993) 555-561